Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
Bergers
G
G
Department of Neurological Surgery, Cancer Centers, University of California, San Francisco, California 94143, USA.
Hanahan
D
D
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018273:Carcinoma, Islet Cell / Q000098:blood supply* / Q000188:drug therapy*; D019454:Chronotherapy; D007211:Indoles / Q000037:antagonists & inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000008:administration & dosage; D011758:Pyrroles / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D013876:Thiophenes / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011758:Pyrroles; D013876:Thiophenes; D010649:Phenylalanine; C116890:Semaxinib; C080985:batimastat; D040262:Receptors, Vascular Endothelial Growth Factor